KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Gains from Sales and Divestitures (2016 - 2017)

Idexx Laboratories has reported Gains from Sales and Divestitures over the past 7 years, most recently at $155000.0 for Q4 2017.

  • Quarterly results put Gains from Sales and Divestitures at $155000.0 for Q4 2017, down 8.82% from a year ago — trailing twelve months through Dec 2017 was $155000.0 (down 8.82% YoY), and the annual figure for FY2017 was $155000.0, down 8.82%.
  • Gains from Sales and Divestitures for Q4 2017 was $155000.0 at Idexx Laboratories, down from $170000.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for IDXX hit a ceiling of $196000.0 in Q4 2015 and a floor of $122000.0 in Q4 2014.
  • Median Gains from Sales and Divestitures over the past 5 years was $155000.0 (2017), compared with a mean of $156400.0.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 60.66% in 2015 and later decreased 13.27% in 2016.
  • Idexx Laboratories' Gains from Sales and Divestitures stood at $139000.0 in 2013, then fell by 12.23% to $122000.0 in 2014, then soared by 60.66% to $196000.0 in 2015, then dropped by 13.27% to $170000.0 in 2016, then decreased by 8.82% to $155000.0 in 2017.
  • The last three reported values for Gains from Sales and Divestitures were $155000.0 (Q4 2017), $170000.0 (Q4 2016), and $196000.0 (Q4 2015) per Business Quant data.